Psychedelic Rally: Stocks Surge as FDA Ramps Up Reviews
Published on: April 21, 2026, 10:28 a.m. | Source: Devdiscourse
Shares of psychedelic drug developers soared following an executive order by U.S. President Donald Trump calling for faster FDA reviews and increased funding. AtaiBeckley stocks jumped 28%, Compass Pathways rose 37%, Enveric BioSciences surged 140%, and GH Research climbed 24%. This rapid investment signals growing interest in psychedelics.
